"Mad Money" host Jim Cramer shares how you can tell a stock has reached a buyable bottom.» Read More
Regeneron Pharmaceuticals president & CEO Dr. Leonard Schleifer provides insight into the early stages of its macular degeneration drug Eylea, its strong partnership with Sanofi and other drugs in its pipeline to treat allergic diseases.
Acorda Therapeutics president & CEO Dr. Ron Cohen discusses its pipeline and current research, whether epilepsy is an epidemic and its plan for its Diazepam nasal spray.
Twitter has everything a "growth accolyte" could possibly ask for, says "Mad Money" host Jim Cramer.
What to watch in tomorrow's trading session, with Jeff Taylor, Digital Risk Management.
Amy Wu, RBC Capital Markets and Rex Macey, Wilmington Trust discuss their market forecasts from now until the end of the year.
CNBC's Sharon Epperson discusses the day's activity in the commodities markets and looks at where oil and precious metals are likely headed tomorrow.
CNBC's Bob Pisani looks at the day's market action, including an interesting earnings beat for Hertz and great numbers from Michael Kors.
Daniel Wiener, Adviser Investments, and Warren Meyers, Illustro Trading, discuss how weak payroll data may push off tapering and impact the markets.
Bob Doll, Nuveen Asset Management, is looking for free cash flow and prefers cyclical stocks. He also explains why he has no hesitations to put new money to work in this current bull market.
CNBC's Dominic Chu looks at three stocks to watch heading into tomorrow, including Tesla, which beat estimates today, and Ralph Lauren and Time Warner, both of which report tomorrow.
Discussing the Fed next move and the economy, with Dani Hughes, Divine Capital CEO; Rob Bartenstein, Washington Wealth Management; Michael Santoli, Yahoo Finance; and CNBC's Rick Santelli
Do stocks need to fall? Michael Vogelzang, Boston Advisors president & CIO, and Chris Johnson, JK Investment Group, discuss investor sentiment right now.
The FMHR traders reveal their final trades.
Corporate America has been announcing share buybacks at a near record pace, supporting richer stock prices for companies with low earnings growth.
CNBC's Kelly Evans reports on all the market moving events in Europe today, including a subdued economic forecast and banks shares lower.
CNBC's Bob Pisani looks at the huge week ahead for IPO's and asks if this a 'top" for the IPO market?
Retail gasoline prices are falling, Don Luskin, Trend Macro, and Jeff Kilburg, KKM Financial. Luskin says "cheaper gas makes growth possible, and we just need a Republican Congress and a Republican President to take the chains off fracking," says Luskin.
Cubist Pharmaceuticals CEO Michael Bonney discusses the impact to his business from acquiring Optimer and Trius Therapeutics; and what's in the pipeline.
"Mad Money" host Jim Cramer says he would bet good money that Twitter's stock will spike after it comes public.
Graeme Maxton, Member of the global think tank, Club of Rome says Fed tapering anytime soon looks highly unlikely as the global economy and the U.S. markets are addicted to QE.